Wen Gu

Wen Gu

Auto-generated profile, based on publicly available information

Wen Gu

Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Cell Stem Cell
Verified
Journal Article
Closed access
WGWen Gu
Wen Gu
XGXavier Gaeta
Xavier Gaeta
ASAnna Sahakyan
Anna Sahakyan
ACAlanna B. Chan
Alanna B. Chan
CHCandice S. Hong
Candice S. Hong
HCHeather Christofk
Heather Christofk

1 February 2016 in Cell Reports
Verified
Journal Article
Open access
CHCandice Sun Hong
Candice Sun Hong
NGNicholas A. Graham
Nicholas A. Graham
WGWen Gu
Wen Gu
CCCarolina Espindola Camacho
Carolina Espindola Camacho
VMVei Mah
Vei Mah
HCHeather Christofk
Heather Christofk
Monocarboxylate transporter 1 (MCT1) inhibition is thought to block tumor growth through disruption of lactate transport and glycolysis. Here, we show MCT1 inhibition impairs proliferation of glycolytic breast cancer cells co-expressing MCT1 and MCT4 via disruption of pyruvate rather than lactate export. MCT1 expression is elevated in glycolytic breast tumors, and high MCT1 expression predicts poor prognosis in breast and lung cancer patients. Acute MCT1 inhibition reduces pyruvate export but does not consistently alter lactate transport or glycolytic flux in breast cancer cells that co-express MCT1 and MCT4. Despite the lack of glycolysis impairment, MCT1 loss-of-function decreases breast cancer cell proliferation and blocks growth of mammary fat pad xenograft tumors. Our data suggest MCT1 expression is elevated in glycolytic cancers to promote pyruvate export that when inhibited, enhances oxidative metabolism and reduces proliferation. This study presents an alternative molecular consequence of MCT1 inhibitors, further supporting their use as anti-cancer therapeutics.

30 November 2020 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
JKJiyeon Kim
Jiyeon Kim
HLHyun Min Lee
Hyun Min Lee
FCFeng Cai
Feng Cai
BKBookyung Ko
Bookyung Ko
CYChendong Yang
Chendong Yang
RDRalph J. DeBerardinis
Ralph J. DeBerardinis

6 April 2022 in Nature
Verified
Journal Article
Open access
PDF file
ASAshley Solmonson
Ashley Solmonson
BFBrandon Faubert
Brandon Faubert
WGWen Gu
Wen Gu
ARAparna Rao
Aparna Rao
MCMitzy A. Cowdin
Mitzy A. Cowdin
RDRalph J. DeBerardinis
Ralph J. DeBerardinis
Mammalian embryogenesis requires rapid growth and proper metabolic regulation1. Midgestation features increasing oxygen and nutrient availability concomitant with fetal organ development2,3. Understanding how metabolism supports development requires approaches to observe metabolism directly in model organisms in utero. Here we used isotope tracing and metabolomics to identify evolving metabolic programmes in the placenta and embryo during midgestation in mice. These tissues differ metabolically throughout midgestation, but we pinpointed gestational days (GD) 10.5–11.5 as a transition period for both placenta and embryo. Isotope tracing revealed differences in carbohydrate metabolism between the tissues and rapid glucose-dependent purine synthesis, especially in the embryo. Glucose’s contribution to the tricarboxylic acid (TCA) cycle rises throughout midgestation in the embryo but not in the placenta. By GD12.5, compartmentalized metabolic programmes are apparent within the embryo, including different nutrient contributions to the TCA cycle in different organs. To contextualize developmental anomalies associated with Mendelian metabolic defects, we analysed mice deficient in LIPT1, the enzyme that activates 2-ketoacid dehydrogenases related to the TCA cycle4,5. LIPT1 deficiency suppresses TCA cycle metabolism during the GD10.5–GD11.5 transition, perturbs brain, heart and erythrocyte development and leads to embryonic demise by GD11.5. These data document individualized metabolic programmes in developing organs in utero.

2 September 2022 in Science Advances
Verified
Journal Article
Open access
PPPanayotis Pachnis
Panayotis Pachnis
ZWZheng Wu
Zheng Wu
BFBrandon Faubert
Brandon Faubert
ATAlpaslan Tasdogan
Alpaslan Tasdogan
WGWen Gu
Wen Gu
RDRalph J. DeBerardinis
Ralph J. DeBerardinis
In mice and humans with cancer, intravenous 13 C-glucose infusion results in 13 C labeling of tumor tricarboxylic acid (TCA) cycle intermediates, indicating that pyruvate oxidation in the TCA cycle occurs in tumors. The TCA cycle is usually coupled to the electron transport chain (ETC) because NADH generated by the cycle is reoxidized to NAD + by the ETC. However, 13 C labeling does not directly report ETC activity, and other pathways can oxidize NADH, so the ETC’s role in these labeling patterns is unverified. We examined the impact of the ETC complex I inhibitor IACS-010759 on tumor 13 C labeling. IACS-010759 suppresses TCA cycle labeling from glucose or lactate and increases labeling from glutamine. Cancer cells expressing yeast NADH dehydrogenase-1, which recycles NADH to NAD + independently of complex I, display normalized labeling when complex I is inhibited, indicating that cancer cell ETC activity regulates TCA cycle metabolism and 13 C labeling from multiple nutrients.

14 June 2024 in Science
Verified
Journal Article
Closed access
XWXun Wang
Xun Wang
CMCameron J. Menezes
Cameron J. Menezes
YJYuemeng Jia
Yuemeng Jia
YXYi Xiao
Yi Xiao
SVSiva Sai Krishna Venigalla
Siva Sai Krishna Venigalla
PMPrashant Mishra
Prashant Mishra
Mitochondria are critical for proper organ function and mechanisms to promote mitochondrial health during regeneration would benefit tissue homeostasis. We report that during liver regeneration, proliferation is suppressed in electron transport chain (ETC)–dysfunctional hepatocytes due to an inability to generate acetyl-CoA from peripheral fatty acids through mitochondrial β-oxidation. Alternative modes for acetyl-CoA production from pyruvate or acetate are suppressed in the setting of ETC dysfunction. This metabolic inflexibility forces a dependence on ETC-functional mitochondria and restoring acetyl-CoA production from pyruvate is sufficient to allow ETC-dysfunctional hepatocytes to proliferate. We propose that metabolic inflexibility within hepatocytes can be advantageous by limiting the expansion of ETC-dysfunctional cells.